Ascierto et al. performed a randomized phase 2 trial enrolling 60 Caucasian patients with BRAF V600-mutant metastatic melanoma who were treated with a triple-combination therapy, including dabrafenib, trametinib, and pembrolizumab. Here, BRAF is linked to metastatic melanoma.